RTP Mobile Logo
Breast Cancer Update, Issue 1, 2012
Released April 2012

Featuring interviews with Drs Edith A Perez, Mark D Pegram, Beth Overmoyer and Sara A Hurvitz. (Text and Audio Content)

CE Disclosures and Faculty Information


    Breast cancer continues to be one of the most rapidly evolving fields in medical oncology. Results from numerous ongoing clinical trials lead to the continual emergence of new therapeutic agents, treatment strategies and diagnostic and prognostic tools. In order to offer optimal patient care — including the option of clinical trial participation — the practicing cancer clinician must be well informed of these advances. Featuring expert perspective on the latest research developments, this CME activity is designed to assist medical oncologists, hematologist-oncologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.


    • Determine the utility of genomic assays in counseling patients with DCIS or ER-positive early breast cancer about their risk of recurrence and the potential benefits of radiation therapy or adjuvant chemotherapy, respectively.
    • Develop evidence-based treatment approaches for patients diagnosed with HER2-positive breast cancer in the neoadjuvant, adjuvant and metastatic settings.
    • Evaluate the unique mechanisms of action and emerging clinical trial data with novel anti-HER2 agents under investigation in breast cancer.
    • Formulate individualized approaches to first- and later-line therapy for patients with HER2-negative metastatic breast cancer.
    • Recall emerging data on the role of mTOR inhibition in reversing resistance to trastuzumab and endocrine therapy in metastatic breast cancer in preparation for the potential availability of this treatment approach.
    • Counsel appropriately selected patients with breast cancer about the supportive and therapeutic role of bisphosphonates and other bone-targeted agents in disease management.


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    This CME activity contains both audio and print components. The participant should listen to the audio MP3s and read the text portion. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.
    CME credit is no longer available for this issue


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDrs Perez and Overmoyer had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr PegramAdvisory Committee: Amgen Inc, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, Millennium: The Takeda Oncology Company; Consulting Agreement: Genentech BioOncology; Data and Safety Monitoring Board: Pfizer Inc. Dr HurvitzPaid Research: Amgen Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi; Paid Travel: Roche Laboratories Inc.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Inctye Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Genentech BioOncology, Genomic Health Inc and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: April 2012
    Expiration date: April 2013

Acknowledge and close

Listen to audio:
Breast Cancer Update, Issue 1, 2012
Released April 2012

Featuring interviews with Drs Edith A Perez, Mark D Pegram, Beth Overmoyer and Sara A Hurvitz. (Text and Audio Content)

Read print: